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Abstract
Cancer patients rely on multiple sources of support when making treat-
ment decisions; however, most research studies examine the influence of 
health care provider support while the influence of family member sup-
port is understudied. The current study fills this gap by examining the in-
fluence of health care providers and partners on decision-making satisfac-
tion. In a cross-sectional study via an online Qualtrics panel, we surveyed 
cancer patients who reported that they had a spouse or romantic partner 
when making cancer treatment decisions (n = 479). Decisional support was 
measured using 5-point, single-item scales for emotional support, informa-
tional support, informational-advice support, and appraisal support. De-
cision-making satisfaction was measured using Holmes-Rovner and col-
leagues’ (1996) Satisfaction With Decision Scale. We conducted a mediated 
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regression analysis to examine treatment decision-making satisfaction for 
all participants and a moderated mediation analysis to examine treatment 
satisfaction among those patients offered a clinical trial. Results indicated 
that partner support significantly and partially mediated the relationship 
between health care provider support and patients’ decision-making sat-
isfaction but that results did not vary by enrollment in a clinical trial. This 
study shows how and why decisional support from partners affects com-
munication between health care providers and cancer patients. 
In the United States, cancer is the second leading cause of death 
(American Cancer Society, 2015), with 40% of adults estimated to 
develop cancer in their lifetime (National Cancer Institute, 2014). 
Cancer is considered both a life crisis and an illness that affects pa-
tients’ family and friends (National Cancer Institute, 2014). To cope 
with cancer and receive assistance with treatment decision making 
(DM), patients turn to health care providers (HCPs) and loved ones 
as sources of support when considering information about their diag-
nosis and treatment options (Arora, Finney Rutten, Gustafson, Moser, 
& Hawkins, 2007; Siminoff, Zyzanski, Rose, & Zhang, 2008). The DM 
process is stressful for patients and their families as they consider 
types of available treatment, weigh treatment benefits and risks, cope 
with uncertainty, and manage the additional burden on themselves 
and their families (e.g., treatment side effects, transportation costs, fi-
nancial concerns; Siminoff, 2013). 
Despite the team-centered nature of cancer care communication, 
however, medical DM research has historically focused on commu-
nication between the patient and HCP (Street, 2013), with less DM 
research focused on the patient and family (Krieger et al., 2015). Fur-
thermore, as scholars have noted, the role of communication from both 
family members and HCPs during this DM process is understudied 
(Albrecht, Penner, Cline, Eggly, & Ruckdeschel, 2009; Arora, Street, 
Epstein, & Butow, 2009; Krieger, 2014; Quaschning, Körner, & Wirtz, 
2013). In addition, treatment decisions that involve scientific or medi-
cal uncertainty (i.e., unknown effectiveness of treatment) or risk (i.e., 
unknown side effects), such as clinical trials (CTs), can be especially 
problematic for patients’ DM satisfaction (Politi, Clark, Ombao, Di-
zon, & Elwyn, 2011). Thus, the current article examines patients’ DM 
satisfaction in relation to (a) support from HCPs and partners (i.e., 
significant others) and (b) patients’ specific CT decision. 
P a l m e r -W a c k e r l y  e t  a l .  i n  J o u r n a l  o f  H e a l t H  C o m m u n i C a t i o n  22  (2017 )      3
Decisional Support 
One way to examine others’ influence on patients’ treatment DM is 
to consider enacted social support, or how supportive messages are 
communicated (Goldsmith, 2004). This definition of support is dif-
ferent from other definitions of social support that focus on the quan-
tity, frequency, structure, and availability of perceived social support, 
which, unlike enacted support, do not consider the quality and ap-
propriateness of support (Goldsmith, 2004). Enacted social support 
primarily includes four dimensions: emotional support (i.e., expres-
sions of caring, concern, and empathy), informational support (i.e., 
information and advice), tangible support (i.e., offers of goods and 
services), and appraisal support (i.e., providing new perspectives on 
problems; Goldsmith & Albrecht, 2011). 
Social support given and received during a DM context has been 
defined as decisional support (Krieger, 2014). Decisional support var-
ies according to individual preferences of patients and families and 
ranges from patient autonomy (the patient assumes/controls all de-
cisional rights and responsibilities) to patient interdependence (the 
patient gives some/all decisional rights and responsibilities to fam-
ily members; for a review, see Krieger, 2014). When aligned between 
patients and family members, decisional support can result in pos-
itive health outcomes (e.g., less distress for the patient); however, it 
can also increase patients’ distress if this support leads to conflict 
between decisional partners about treatment preferences (Siminoff, 
Rose, Zhang, & Zyzanski, 2006). 
HCP and Partner Decisional Support 
In recent decades, HCPs have increasingly focused on the treatment 
goals of patients through patient-centered communication (PCC), 
which includes fostering healing relationships, exchanging informa-
tion, responding to emotions, making decisions, and managing uncer-
tainty (Arora et al., 2009). A core tenet of PCC is the belief that HCPs 
should support the needs of the whole person, which includes con-
sidering the influence of family members in the DM process (Epstein 
& Street, 2007). Family members provide decisional support to pa-
tients by assisting patients in seeking, organizing, and processing in-
formation for health decisions, including finding an HCP, receiving 
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advice about cancer treatment, and describing symptoms to provid-
ers (Krieger et al., 2015; Siminoff et al., 2006). However, family mem-
bers have also been shown to pressure patients to choose treatments 
that are less burdensome to the family and adhere to patients’ fami-
ly’s values instead of HCP recommendations (Siminoff, 2013). In can-
cer DM, spouses are often the primary source of support (Miller & 
Caughlin, 2013), and extant research associates spousal communi-
cation with psychosocial outcomes, such as distress and adjustment 
to diagnosis (Harris et al., 2009). Thus, scholars have called for more 
research determining the role of family support in (a) patient–pro-
vider communication and (b) patients’ psychosocial outcomes (e.g., 
Albrecht et al., 2009; Ballard-Reisch & Letner, 2003; Harris et al., 2009; 
Street, 2013). Given that patients may differ in their perceived deci-
sional support from HCPs and partners (Siminoff, 2013), we exam-
ine how partner support is related to the relationship between HCP 
support and patient DM satisfaction. 
One possibility is that partner support may partially mediate the 
relationship between HCP support and patient DM satisfaction for 
three reasons. First, some patients, even if they have supportive fam-
ily members, prefer to rely primarily on HCP support to make their 
treatment decision (Krieger, 2014). Thus, we expect a direct relation-
ship to exist between HCP support and patient DM satisfaction. Sec-
ond, in a clinical interaction, HCPs typically first initiate conversa-
tions about treatment with patients and supportive others who may 
be attending the appointment (Street, 2013). Third, although patient 
conversations with supportive others often continue beyond the clin-
ical interaction before a decision is made by patients, HCPs have the 
ability to improve family support by encouraging patients to talk to 
family members to ask for the emotional, informational, and tangible 
help they need (Street, 2013; Street, Makoul, Arora, & Epstein, 2009). 
Building on this past research, we conceptualize HCP support as oc-
curring before partner support in patients’ DM process (see Figure 1). 
Clinical Trial Decision-Making 
CTs are viewed as a critical resource for improving cancer care 
through treatment advances (Baquet, Commiskey, Mullins, & Mishra, 
2006); however, fewer than 5% of cancer patients enroll in CTs 
(Umutyan et al., 2008). Research has primarily focused on identifying 
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enrollment barriers, yet scholars agree that more research should fo-
cus on patients’ quality of DM and family and HCP support for those 
decisions (Stepan et al., 2011; Yang et al., 2010). One study found that 
patients felt more confident about their CT decision when they had 
more information and alliance with HCPs and family members (Al-
brecht et al., 2008). As a result, patients who enroll in a CT might have 
higher DM satisfaction when they view members of their decisional 
support team (i.e., family and HCPs) as participating in their treat-
ment decisions (i.e., giving support). 
Based on the literature discussed previously, we present the fol-
lowing hypotheses and research questions. Where we know the di-
rection of relationships based on extant research, we hypothesize the 
predicted relationships between variables. Where relationships are 
not established in the literature, we present research questions to ex-
plore the connections between variables. Thus, we present the hy-
potheses and research questions in the order that the tested relation-
ships appear in the models (see Figures 1 and 2): 
Fig. 1. Theoretical model of mediation of social support and decision-making sat-
isfaction (PROCESS Model 4). Indirect effect = (a × b). Total effect (c) = c′ + (a × b). 
HCP = health care provider. 
Fig. 2. Theoretical model of moderated mediation of CT enrollment on social sup-
port and decision-making satisfaction (PROCESS Model 14). Indirect effect = (a × 
b). Total effect (c) = c′ + (a × b). HCP = health care provider; CT = clinical trial. 
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Hypothesis 1: Patients’ perceived decisional support from HCPs 
will relate positively to patients’ cancer treatment DM 
satisfaction. 
Research Question 1: How will patients’ perceived decisional sup-
port from partners relate to patients’ DM satisfaction? 
Research Question 2: How will patients’ perceived decisional sup-
port from HCPs relate to patients’ perceived decisional 
support from partners? 
Hypothesis 2: Patients’ perceived partner support will partially me-
diate the effects of patients’ perceived HCP support on 
patient DM satisfaction. 
In addition, we examine whether the relationship between deci-
sional support and patient DM satisfaction varies with whether pa-
tients enroll in a CT (see Figure 2). Thus, we present the final research 
question: 
Research Question 3: Does the decision to enroll in a CT moderate 
the effects of patients’ perceived partner and HCP sup-
port on patients’ DM satisfaction? 
Method 
Sample and Recruitment 
Participants (N = 667) included patients ages 18 years or older who 
had received a cancer diagnosis within the past 2 years. Ages ranged 
from 18 to 89 (M = 48.9, SD = 17.0). A subsample of participants (n 
= 481) responded “yes” to the question “At the time you were mak-
ing decisions about your cancer treatment, did you have a significant 
other (spouse, partner, etc.)?” However, two participants in this sub-
set were removed from final analyses because of missing data on HCP 
support and income measures. Thus, analyses were subsequently 
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restricted to a subsample of 479 participants. The majority of these 
participants were female and White, with ages ranging from 20 to 
89 years old (M = 48.1, SD = 16.5). Participant characteristics are re-
ported in Table 1. 
Table 1. Participant statistics 
  Partner and 
Characteristic  Total sample   HCP support  CT offer 
 (N = 667)  (n = 479)  (n = 104) 
Age 
    18–24  38 (5.7)  15 (8.1)  2 (1.9) 
    25–34  144 (21.6)  32 (17.3)  31 (29.8) 
    35–44  114 (17.1)  23 (12.4)  31 (29.8) 
    45–54  96 (14.4)  29 (15.7)  18 (17.3) 
    55–64  122 (18.3)  36 (19.5)  12 (11.5) 
    65–74  108 (16.2)  36 (19.5)  9 (8.7) 
    75+  45 (6.7)  14 (7.6)  1 (1.0) 
Sex 
    Female  416 (62.4)  293 (61.2)  71 (68.3) 
    Male  251 (37.6)  186 (38.8)  33 (31.7) 
Race 
    White  568 (85.2)  408 (85.2)  75 (72.1) 
    African American  50 (7.5)  34 (7.1)  12 (11.5) 
    Asian/Asian American/Pacific Islander  35 (5.2)  26 (5.4)  14 (13.5) 
    Native American/Eskimo  4 (0.6)  3 (0.6)  0 (0) 
    Other  10 (1.5)  8 (1.7)  3 (2.9) 
Education 
    HS incomplete  12 (1.8)  6 (1.3)  0 (0) 
    HS graduate  93 (13.9)  67 (14.0)  10 (9.6) 
    Technical/trade/vocational after HS  55 (8.2)  40 (8.4)  11 (10.6) 
    Some college  192 (28.8)  141 (29.4)  30 (28.8) 
    College graduate (4-year degree)  233 (34.9)  171 (35.7)  38 (36.5) 
    Postgraduate  82 (12.3)  54 (11.3)  15 (14.4) 
U.S. annual income 
    Less than $10,000  18 (2.7)  9 (1.9)  2 (1.9) 
    $10,000 to less than $20,000  47 (7.0)  15 (3.1)  4 (3.8) 
    $20,000 to less than $30,000  73 (10.9)  44 (9.2)  4 (3.8) 
    $30,000 to less than $40,000  87 (13.0)  59 (12.3)  17 (16.3) 
    $40,000 to less than $50,000  64 (9.6)  46 (9.6)  7 (6.7) 
    $50,000 to less than $75,000  160 (24.0)  123 (25.7)  27 (26.0) 
    $75,000 to less than $100,000  113 (16.9)  92 (19.2)  22 (21.2) 
    $100,000 to less than $150,000  80 (12.0)  70 (14.6)  16 (15.4) 
    $150,000+  24 (3.6)  21 (4.4)  5 (4.8) 
Data are n (%). HCP = health care provider; CT = clinical trial; HS = high school. 
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As for CT offers, approximately 20% (n = 133) of the original sam-
ple of patients (N = 667) responded “yes” to the question “Were you 
offered an opportunity to participate in a cancer research study as 
part of your treatment?” Likewise, within the subsample of 479 par-
ticipants with partner support, only 104 (21.7%) of these participants 
were offered a CT (see Table 2). Among these 104 participants, ages 
ranged from 23 to 78 (M = 42.9, SD = 12.9). The most common types 
of cancer were breast and prostate, with more than a third of partici-
pants having received a cancer diagnosis in the 6 months prior to par-
ticipating in our study (see Table 2 for participants’ clinical cancer in-
formation, such as diagnosis and CT enrollment). 
Table 2. Participant clinical information 
   Partner and 
Characteristic  Total sample  HCP support  CT offer  
  (N = 667)  (n = 479)  (n = 104) 
CT offer 
 Yes  133 (19.9)  104 (21.7)  104 (100.0) 
 No  534 (80.1)  375 (78.3)  0 (0.0) 
CT enrollment 
 Yes  78 (11.7)  66 (13.8)  66 (63.5) 
 No  589 (88.3)  413 (86.2)  38 (36.5) 
Time since most recent cancer diagnosis 
 Less than 3 months ago  92 (13.8)  69 (14.4)  17 (16.3) 
 3–6 months ago  134 (20.1)  93 (19.4)  21 (20.2) 
 7–12 months ago  195 (29.2)  141 (29.4)  40 (38.5) 
 13–24 months ago  246 (36.9)  176 (36.7)  26 (25.0) 
Most recent cancer type 
 Breast  195 (29.2)  152 (31.7)  48 (46.2) 
 Prostate  86 (12.9)  67 (14.0)  16 (15.4) 
 Colon or rectal  39 (5.8)  28 (5.8)  10 (9.6) 
 Lung  70 (10.5)  43 (9.0)  11 (10.6) 
 Melanoma  88 (13.2)  62 (12.9)  13 (12.5) 
 Bladder  19 (2.8)  14 (2.9)  2 (1.9) 
 Other  198 (29.7)  137 (28.6)  18 (17.3) 
Chances cancer is/will be cured 
 90% or better  270 (40.5)  191 (39.9)  20 (19.2) 
 About 75%  152 (22.8)  116 (24.2)  34 (32.7) 
 About 50%–50%  143 (21.4)  97 (20.3)  28 (26.9) 
 About 25%  29 (4.3)  24 (5.0)  10 (9.6) 
 10% or less  24 (3.6)  17 (3.5)  7 (6.7) 
 I don’t know  49 (7.3)  34 (7.1)  5 (4.8) 
Data are n (%). HCP = health care provider; CT = clinical trial. 
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For 1 week in May 2014, participants were recruited from an on-
line Qualtrics panel (i.e., a pool of U.S. adults who have volunteered 
to participate in online survey research via Qualtrics). Participants 
were randomly selected to participate in this institutional review 
board–approved study through an e-mail invitation with an embed-
ded secure, individualized link to the survey. Survey questions fo-
cused on the attitudes and experiences of cancer survivors. Responses 
were anonymous and confidential, and no personal identifiers were 
linked to participants. 
Participants who chose to opt in to the study read an introduc-
tory page that described the study and its purpose and requested 
their consent to participate. Once they gave their consent, partici-
pants completed the survey. After survey completion, participants 
received a debriefing statement, which provided contact informa-
tion for the principal investigators if they had any questions about 
the survey or their participation. All study participants received a 
cash value reward that was credited to their member account on the 
site and could be redeemed for a gift card (e.g., Amazon.com, Payo-
neer prepaid debit, restaurants. com). The reward amount was based 
on recruiting incentives, which were adjusted for survey length and 
target audience. 
Questionnaire 
Decisional Support Measures 
Decisional support measures were adapted from established def-
initions of enacted support (Goldsmith, 2004) and based on the so-
cial support dimensions reported by patients to be the most impor-
tant types of decisional support in their cancer CT treatment DM in a 
previous study (Krieger, Palmer-Wackerly, Dailey, & Krok, 2013). Be-
cause this was the first time this scale was being used, we also wanted 
to test the feasibility of using a shortened decisional support scale. 
Decisional support was measured using a 5-point Likert scale ask-
ing whether patients had received any treatment DM help by others 
(a) “showing care and concern for me” (i.e., emotional support), (b) 
“giving me valuable information about my treatment options” (i.e., 
informational support), (c) “giving me advice about which treatment 
option would be better for me” (i.e., informational advice support), 
and (d) “giving me a different point of view” (i.e., appraisal support). 
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Responses ranged from strongly disagree (1) to strongly agree (5), and 
the scale was repeated across two separate support sources: HCP (i.e., 
oncologist) and partner (i.e., significant other). Scale items resulted 
in reliability for partner support (α = .84) and HCP support (α = .85). 
A principal component analysis (PCA) was conducted on the de-
cisional support items. We wanted to examine whether the scale re-
ported that participants recognized support types as separate and dis-
tinct subconcepts or whether participants viewed support types as 
belonging to only one concept. For each support source, a PCA was 
conducted for decisional support survey items. All coefficients in the 
correlation matrix were 0.3 and above. Kaiser–Meyer–Olkin values 
were 0.781 (HCP) and 0.775 (partner), and Bartlett’s test of spheric-
ity was significant for both sources, thus making factor analysis ap-
propriate for both of these source scales (Pallant, 2013). Analysis of 
both scales resulted in one component with eigenvalues exceeding 
1: 2.848 (HCP) and 2.726 (partner), which explained 71% (HCP) and 
68% (partner) of the variance. Thus, we combined scale items for each 
source separately into two variables (HCP and partner) by using the 
mean score across each case for each support source. 
CT Participation Measure 
CT participation was measured by asking patients who were of-
fered a CT the following: “Did you agree to participate in the cancer 
research study you were offered?” Responses were “yes” and “no.” 
DM Satisfaction Measures 
DM satisfaction was measured using a 5-point Likert scale cre-
ated from four questions from the Satisfaction With Decision Scale 
(Holmes-Rovner et al., 1996): (a) “I am satisfied that I was adequately 
informed about the issues important to my decision,” (b) “The treat-
ment decision I made was the best decision possible for me person-
ally,” (c) “I am satisfied with the outcome of my decision,” and (d) “I 
am satisfied that my decision was consistent with my personal val-
ues.” Possible responses ranged from strongly disagree (1) to strongly 
agree (5). Scale reliability was high (α = .88). Using the guidelines 
above for PCA (Pallant, 2013), results showed that the test was ap-
propriate and that one component was present with an eigenvalue 
exceeding 1: 2.968, which explained 74% of the variance. Thus, scale 
items were combined into one variable by using the mean score of 
scale items for each case. 
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Some researchers claim that quality DM is more important than sat-
isfaction with DM in determining patients’ well-being. These reasons 
include the need to accurately assess patients’ knowledge about op-
tions, patients’ understanding of risk involved with treatments, and/
or how well the DM process matches patients’ value system (Politi et 
al., 2011). In consideration of these reasons, we chose Holmes-Rovner 
and colleagues’ (1996) satisfaction with DM scale because it privileges 
patients’ perspective in asking patients to evaluate how informed they 
believed they were, how good the decision was for them, how satis-
fied they were with the outcome, and how consistent the decision was 
with their personal values. Likewise, patients do not always engage in 
systematic processing when making treatment decisions and instead 
engage in naturalistic (i.e., intuition-based) and/or heuristic process-
ing (Epstein, 2013). Patients desire different levels of information de-
pending on where they are located in the illness trajectory (Marcus 
et al., 2013). In the cancer context specifically, patients have initially 
reported feeling overwhelmed and experiencing difficulty process-
ing information after their diagnosis. However, it is precisely at this 
moment that treatment options are often discussed because of medi-
cal concerns about cancer progression, and this is why it is often sug-
gested that patients bring loved ones to their appointments (Krieger, 
2014). These appointments can also be overwhelming for caregivers, 
and factors such as motivation, knowledge, and communication skills 
have been shown to influence how well people understand and com-
municate with HCPs about health information (Epstein & Street, 2007). 
Thus, satisfaction with DM, although not the only measure for qual-
ity of DM, is an important indicator of decisional quality because it 
indicates that patients have met their goals and considered their val-
ues (i.e., PCC), which have been linked to less decisional conflict and 
increased well-being (Glass et al., 2012). 
Data Analysis 
All analyses of survey information about cancer treatment attitudes 
were conducted in SPSS (Version 22; IBM, New York, NY). Frequen-
cies and distributions of demographic and behavioral variables (see 
Table 1) and the reliability of scale items were assessed. Three key 
variables (i.e., HCP support, partner support, and DM satisfaction) 
were negatively skewed; thus, they were transformed by reflect-
ing and inversing the scores to allow for more normally distributed 
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responses in order to meet the statistical assumptions of the tech-
niques below (Tabachnick & Fidell, 2014, p. 87). 
Using the PROCESS macro in SPSS, we tested the hypothesized 
partial mediation model (see Figure 1; Model 4 in PROCESS) and 
moderated mediation model (see Figure 2; Model 14 in PROCESS; 
Hayes, 2013; Preacher & Hayes, 2004; Preacher, Rucker, & Hayes, 
2007).Within the PROCESS macro of SPSS, Model 4 tests a simple me-
diation model, whereas Model 14 tests a moderated mediation model 
with the moderation occurring between the mediating and dependent 
variables (see Figures 1 and 2; Hayes, 2013; Preacher & Hayes, 2004). 
Through these analyses, the relationships between all variables were 
estimated. In PROCESS Model 4, the mediation model’s test of signif-
icance for the indirect effect was conducted to estimate path a from 
the predictor variable (i.e., HCP support) to the mediating variable 
(i.e., partner support), path b from the mediating variable to the out-
come variable (i.e., DM satisfaction), and path c′ from the predictor 
variable to the outcome variable (see Figure 1). The indirect effect was 
quantified as the product of the direct effect of HCP support on part-
ner support and the direct effect of HCP support on DM satisfaction. 
The total effect of HCP support on DM satisfaction (path c) was esti-
mated by adding the direct effect (path c′) and indirect effect (paths 
a × b; Hayes, 2013; Preacher & Hayes, 2004). Bootstrapping (i.e., indi-
rect effects estimated from repeated sampling) was conducted in or-
der to generate a valid 95% confidence interval for statistical inference 
(Hayes, 2013; Preacher & Hayes, 2004). All analyses controlled for sex, 
age, education, ethnicity, and income (see Table 1 for frequencies). 
A moderated mediation analysis was conducted using partici-
pants who had been offered the opportunity to participate in a CT 
and reported a romantic partner (n = 104). Using the PROCESS macro 
in SPSS, we used Model 14 (see Figure 2) to conduct a test of signifi-
cance for the indirect and conditional effects to estimate path a from 
the predictor variable (i.e., HCP support) to the mediating variable 
(i.e., partner support), path b from the mediating variable to the out-
come variable (i.e., DM satisfaction), path c′ from the predictor vari-
able to the outcome variable, and the conditional effect of a CT de-
cision (yes/no) on DM satisfaction. Indirect and direct effects were 
estimated using the same procedures detailed in the previous para-
graph. Bootstrapping was conducted with 5,000 samples to test sig-
nificance and obtain a valid 95% confidence interval (Hayes, 2013; 
Preacher & Hayes, 2004; Preacher et al., 2007). 
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Results 
HCP Support and DM Satisfaction (Hypothesis 1) 
Descriptive statistics and Pearson’s correlation test results are re-
ported in Table 3. Hypothesis 1 predicted that HCP support would 
be positively associated with patients’ DM satisfaction. After we con-
trolled for demographic variables, results from a mediated regression 
model show a significant direct effect of HCP support on the likeli-
hood of DM satisfaction (path c′ in Hayes, 2013; Preacher & Hayes, 
2004; b = 0.420, p < .001; see Table 4). Thus, independent of partner 
support, a direct effect existed between HCP support and the likeli-
hood of reporting patient DM satisfaction. Thus, Hypothesis 1 was 
supported. 
Partner Support and DM Satisfaction (Research Question 1) 
Research Question 1 explored the association between partner sup-
port and patients’ DM satisfaction. After we controlled for demo-
graphic variables, the mediation model found that the direct effect of 
partner support on DM satisfaction (path b in Hayes, 2013) was pos-
itive and significant (b = 0.090, p < .001; see Table 4). 
Table 3. Descriptive statistics and Pearson’s correlations between variables 
      Pearson’s r  
Variable  M  SD  Range  1  2  3  4 
1. Partner support  3.9  0.9  1.0–5.0  —  .481**  .156†  .213** 
2. HCP support  4.1  0.8  1.0–5.0   —  .064  .429** 
3. Clinical trial decision        —  .08 
4. DM satisfaction  4.4  0.7  1.0–5.0     — 
Age  48.2  16.6  20.0–89.0  −.32**  −.12**  −.01  .19** 
Sex (1 = male, 2 = female)     .11*  .11*  −.18*  .09† 
Education     .02  −.06  .01  −.05 
Ethnicity     .06  .03  −.01  −.08† 
Income     .04  .01  .03  .03 
HCP = health care provider; DM = decision making. 
† p < .10 ; * p < .05 ; ** p < .001 
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HCP Support and Partner Support (Research Question 2) 
Research Question 2 explored the association between HCP support 
and partner support. After we controlled for demographic variables, re-
sults from a mediated regression test found that the direct effect of HCP 
support on partner support (path a in Hayes, 2013; Preacher & Hayes, 
2004) was positive and significant (b = 0.483, p < .001; see Table 4). 
Mediation of Partner Support on HCP Support and Patient DM 
Satisfaction (Hypothesis 2) 
Hypothesis 2 predicted that partner support would indirectly mediate 
the relationship between HCP support and patient DM satisfaction 
(see Figure 1). Results from the model indicated a partial mediation 
with both an indirect and direct effect of HCP support on patients’ 
DM satisfaction (see Table 4). The indirect effect of HCP support on 
DM satisfaction through partner support was the product of paths a 
and b: 0.483 × 0.090 = 0.044. This means that a patient who reported 
1 unit higher on the HCP support scale was estimated to report 0.044 
units higher in DM satisfaction through the effect of partner support. 
The indirect effect was statistically different from zero, as evidenced 
by the 95% confidence interval for the indirect effect created by the 
5,000 bootstrap samples [0.001, 0.089]. We estimated the total effect 
of HCP support on DM satisfaction (path c in Hayes, 2013; Preacher 
& Hayes, 2004) by adding the direct effect and indirect effect: 0.420 + 
0.044 = 0.463 (p < .001). Thus, Hypothesis 2 was supported through a 
partial and significant mediation effect of partner support on the re-
lationship between HCP support and patient DM satisfaction. 
Table 4. Regression results for mediation 
Panel A: Variable  Coefficient  t  p  CI 
DM satisfaction regressed on HCP support (c)  0.463  11.125  <.001  [0.382, 0.545] 
Partner support regressed on HCP support (a)  0.483  11.434  <.001  [0.400, 0.566] 
DM satisfaction regressed on partner support  0.090  1.990  <.05  [0.001, 0.179] 
   controlling for HCP support (b) 
DM satisfaction regressed on HCP support  0.420  8.950  <.001  [0.328, 0.512] 
   controlling for partner support (c′)  
CI = confidence interval; DM = decision making; HCP = health care provider
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CT Enrollment Interaction Effect (Research Question 3) 
Research Question 3 examined whether the relationship between de-
cisional support from HCPs and partners and DM satisfaction var-
ied with CT enrollment. A correlation matrix indicated the strength 
and significance of support source on CT decision (see Table 3). Both 
HCP and partner support were positively correlated with CT deci-
sion, though the relationships were not significant. A moderated me-
diation regression analysis (see Figure 2) showed that HCP support 
was positively and significantly associated with patients’ DM satis-
faction (b = 0.370, p < .001) and that no other relationships were sig-
nificant. Specifically, the interaction between partner support and CT 
decision was positive though not significantly different from zero (b = 
0.038, p = .78; see Table 5). Thus, the results did not support the mod-
erated effect of CT enrollment on the mediation of partner support on 
the relationship between HCP support and patient DM satisfaction. 
Discussion 
Scholars have called for more research that identifies factors, such as 
family social support, that affect the relationship between HCP com-
munication and treatment outcomes (Epstein, 2013; Krieger, 2014; 
Street, 2013). Our results demonstrate that partner support partially 
mediates the relationship between HCP support and patients’ DM 
satisfaction within the cancer treatment context. In addition, our 
results showed that both HCP and partner support were signifi-
cant, independent, and positive predictors of patient DM satisfac-
tion, even after we controlled for demographic characteristics (e.g., 
Table 5. Regression results for moderated mediation 
Panel A: Variable  Coefficient  t  p  CI 
Decision-making satisfaction regressed on 
HCP support  0.370  4.409  <.001  [0.204, 0.537] 
Partner support  0.075  0.662  .51  [−0.148, 0.297] 
CT enrollment  −0.020  −0.220  .83  [−0.198, 0.158] 
Interaction (Partner Support × CT)  0.038  0.277  .78  [−0.236, 0.313] 
CI = confidence interval; HCP = health care provider; CT = clinical trial
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gender, race). Our results confirm that HCP support is a stronger 
predictor of DM satisfaction than partner support but that higher 
HCP support also encourages more partner support, which influ-
ences patients’ decision satisfaction. Results, however, did not vary 
with CT enrollment. 
HCP and Partner Support 
We found that most patients reported that HCP support was highly 
influential in their DM satisfaction. This finding for HCP support 
is encouraging given the focus on patient-centered care in medi-
cal DM and patient perceptions of HCP credibility and knowledge 
(e.g., Street, 2013). This finding shows that for cancer treatment DM, 
patients value the support their HCP gives them, and, when effec-
tive, this support influences patient satisfaction. These findings also 
showed that CT enrollment did not affect the relationship between 
decisional support and patient decisional satisfaction. This result is 
promising for patient well-being in that it may suggest that patients 
are feeling supported in their treatment decision from both partners 
and HCPs, no matter their CT decision. 
Partner support was shown to be positively associated with pa-
tients’ medical DM; however, variability existed among patients in 
the extent to which this support influenced their decision. In addi-
tion, the direct effect on DM satisfaction was small, which supports 
previous cancer DM research in that patients do not always seek 
and/or value support from their family and that, conversely, fami-
lies do not always give the support that a patient desires from them 
(e.g., Krieger, 2014). Patients also viewed types of support (e.g., emo-
tional, informational, advice, and appraisal) as similarly influential 
to their treatment decision for both support sources. Although some 
scholars (e.g., Arora et al., 2007) have suggested using separate di-
mensions of social support, the PCA indicated that decisional sup-
port types blended together for the patients even though support 
sources (i.e., HCP vs. partner) had different associations with deci-
sional satisfaction. A variety of mechanisms could explain this find-
ing: (a) Patients may have wanted to receive both information and 
emotional care from their HCP; (b) by communicating information, 
HCPs were also communicating their concern for patients; and/or 
(c) single-item measures are not distinct enough to identify unique 
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differences among types of decisional support (Arora et al., 2007). 
However, for the purposes of this study, we wanted to explore the 
influence of support source more than support type as well as explore 
the utility of a shortened decisional support scale; thus, the current 
scale was appropriate for our analysis. 
These results also suggest that in addition to PCC with HCPs, pa-
tients could also benefit from PCC with family members— focusing 
on patient goals and values for treatment. Just as shared DM mod-
els between HCPs and patients have moved to a mutually influential 
style of communicating—one that respects patients’ goals and level 
of involvement (Arora et al., 2009)—so too could shared DM models 
with family members incorporate respect for patients’ goals and their 
level of involvement. Of course, PCC may be more emotionally diffi-
cult for caregivers (as opposed to HCPs), who are personally and rela-
tionally invested and perceive cancer to be affecting the entire family 
(Krieger et al., 2015; Hasson-Ohayon, Goldzweig, Braun, & Galin-
sky, 2010). Thus, future family cancer communication interventions 
could explore how to educate both patients and caregivers on the im-
portance of PCC in shared illness identity and its personal and rela-
tional implications, such as identifying and respecting patients’ de-
sire for the family’s level of involvement in DM in order to increase 
patient well-being and decrease decisional conflict for families. 
Strengths and Limitations 
As other researchers have noted, many relational influences (e.g., 
friends, siblings, children) influence the clinical encounter both be-
fore and after these visits (Harris et al., 2009). Strengths of our study 
include a large sample of cancer patients with partners (n = 479), a 
large subsample of patients who were offered a cancer CT and had 
partners (n = 104), and the combined consideration of two relational 
influences (i.e., HCPs and partners) on patients’ DM satisfaction. Al-
though a minority of adult cancer patients (fewer than 5%) enroll in 
a CT (Umutyan et al., 2008), approximately 12% of our total sample 
enrolled in a CT, and 14% of the patients who had partners enrolled 
in a CT. Although our sample participated in CTs at a higher rate 
than the general population, CT participants are often difficult to re-
cruit given their small percentages of enrollment. Thus, the current 
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analyses remain informative in examining the relationship between 
CT decisional support and decisional satisfaction, and the higher per-
centage of CT enrollees is a strength of the study. 
One limitation of our study is that we did not ask about length of 
time since treatment or current cancer diagnosis; thus, we are unsure 
how many patients still had cancer versus how many were in remis-
sion. Because CT participants are difficult to recruit, we asked par-
ticipants to enroll in our study if they had received a cancer diagno-
sis within 2 years (instead of a shorter time frame). It is possible that 
patients in remission may have biased recall around DM indicating 
a more positive experience; however, we believe this limitation to be 
of little concern because participants’ clinical information showed 
that 35% of the 479 cancer participants and 48% of the 104 CT partic-
ipants in our sample reported that they thought their chances of hav-
ing their cancer cured were 50% or less. 
An additional limitation is that our findings only represent can-
cer patients who have significant others. The current study specifi-
cally looked at partner support because partners and HCPs have been 
shown to be the most influential sources of support for cancer pa-
tients (e.g., Miller & Caughlin, 2013). However, the findings cannot 
be generalized to cancer patients who rely on other caregivers, such 
as a close friend, sibling, or child because they either are not mar-
ried, have lost a partner, or find more support in other relationships. 
Future studies should instead consider the combined influence of a 
primary support network source (as opposed to a significant other) 
to account for these differences and increase generalizability among 
cancer patients. This may especially be true for young adult cancer 
patients who may rely more heavily on their parents rather than a 
significant other. 
Finally, we tested our models assuming a temporal relationship 
between HCP support, partner support, and patients’ DM satisfac-
tion. This assumption was made based on three extant findings in the 
literature: (a) Sometimes patients prefer to confer only with HCPs in 
medical DM, (b) HCPs typically initiate treatment conversations in 
a cancer context, and (c) HCPs encourage family/friend support in 
cancer DM (Krieger, 2014; Street, 2013; Street et al., 2009). Though 
a causal relationship cannot be inferred from the cross-sectional 
data provided in this study, the results suggest an explanation for a 
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process (MacKinnon, 2008) through which HCPs influence patients’ 
DM satisfaction (i.e., HCP support leads to partner support, which 
leads to DM satisfaction). Future studies should consider temporal 
study designs to appropriately test causal linkages. Finally, patients 
surveyed through a Qualtrics Web survey present a selection bias in 
any sample because they likely (a) have an interest in research, (b) 
are motivated to participate to receive monetary remuneration, and/
or (c) have more advanced technological skills than the average can-
cer patient. 
Conclusions and Implications 
The goal of this study was to examine the dual influences of both 
HCPs and partners in patients’ medical DM satisfaction. This study 
furthers knowledge of social support by showing how and why sup-
port from partners affects communication between HCPs and patients 
within the cancer clinical DM context. Likewise, support from both 
HCPs and family members did not vary with CT enrollment, which 
shows that patients were satisfied with decisional support and their 
treatment decision no matter if they accepted or declined a CT. With 
continued theoretical development, interventions can be developed 
and tested to ensure that patients’ decisional needs for support are 
met from all medical and social network members. 
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